test

Flynn Management LLC, its general partner

@Deerfield Management Company, L.p. (series C)

Latest period2024 - Q3ReportedManaged Assets$6.693BTotal holdings443
Assets growth rate11.36%Assets growth rate (2-Q avg)7.96%Continuous growth in asset value4 quarters

Portfolio positions

This chart displays the top 10 holdings in Deerfield Management Company, L.p. (series C)'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 443 positions.

Assets under management

The assets under management (AUM) of Deerfield Management Company, L.p. (series C) over the past 10 years (40 quarters) show continuous growth in total asset value over the last 4 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 6.693B in assets, with a quarterly growth rate of 11.36% and a 2-quarter average growth rate of 7.96%. The portfolio is managed by Flynn Management LLC, its general partner, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
0204⤦Alnylam Pharmaceuticals Inc
Recent Activity
New Position
1.75%
$117.092M
100M shares@ $1.18 avg price
0208⤦Alphatec Hldgs Inc
Recent Activity
New Position
1.58%
$105.718M
117.5M shares@ $0.9 avg price
INDVIndivior Plc
Recent Activity
New Position
0.75%
$49.653M
5.093M shares@ $9.76 avg price
BCAXBicara Therapeutics Inc
Recent Activity
New Position
0.69%
$45.723M
1.795M shares@ $25.48 avg price
SVRASavara Inc
Recent Activity
New Position
0.41%
$27.415M
6.466M shares@ $4.24 avg price
ZBIOZenas Biopharma Inc
Recent Activity
New Position
0.4%
$26.445M
1.563M shares@ $16.93 avg price
PCVXVaxcyte Inc
Recent Activity
New Position
0.39%
$25.711M
225,000 shares@ $114.27 avg price
DYNDyne Therapeutics Inc
Recent Activity
New Position
0.24%
$15.649M
435,653 shares@ $35.93 avg price
RXRXRecursion Pharmaceuticals In
Recent Activity
New Position
0.23%
$15.256M
2.315M shares@ $6.59 avg price
CONConcentra Group Holdings Par
Recent Activity
New Position
0.22%
$14.534M
650,000 shares@ $22.36 avg price